2012
DOI: 10.1136/jmedgenet-2012-100973
|View full text |Cite
|
Sign up to set email alerts
|

High-throughput mutation analysis in patients with a nephronophthisis-associated ciliopathy applying multiplexed barcoded array-based PCR amplification and next-generation sequencing

Abstract: We conclude that the combined approach of array-based multiplexed PCR-amplification on a Fluidigm Access Array platform followed by next-generation sequencing is highly cost-efficient and strongly facilitates diagnostic mutation analysis in broadly heterogeneous Mendelian disorders.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

7
136
1

Year Published

2013
2013
2023
2023

Publication Types

Select...
6
1

Relationship

2
5

Authors

Journals

citations
Cited by 109 publications
(144 citation statements)
references
References 45 publications
7
136
1
Order By: Relevance
“…As previously published, median coverage values .203 are sufficient to exclude false-negative results in high-throughput exon sequencing (5,6). In this study, only eight of 143 individuals (5.7%), and 37 of 518 amplicons (7.1%) had a median coverage ,203.…”
Section: Coverage Statisticssupporting
confidence: 57%
See 3 more Smart Citations
“…As previously published, median coverage values .203 are sufficient to exclude false-negative results in high-throughput exon sequencing (5,6). In this study, only eight of 143 individuals (5.7%), and 37 of 518 amplicons (7.1%) had a median coverage ,203.…”
Section: Coverage Statisticssupporting
confidence: 57%
“…Mutation analysis was performed using a barcoded multiplex PCR-based approach, as previously described (5,6). We designed 518 target-specific primers for 381 coding exons and the adjacent splice sites of 30 genes that are known monogenic causes of NL/NC (defined by OMIM; www.ncbi.nlm.nih.gov/omim).…”
Section: Mutation Analysismentioning
confidence: 99%
See 2 more Smart Citations
“…Black line indicates the correlation of PCOLCE2 mRNA level with GFR. group in a rare disease cohort (Halbritter et al 2012;Gadegbeku et al 2013).…”
Section: Discussionmentioning
confidence: 99%